Login
$SRZN
$32.32 +$0.71 (2.25%) Live

$SRZN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 424B5
16 Nov 2026 8-K: Entry into a Material Definitive Agreement

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

16 Nov 2026 SCHEDULE 13G
13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 FWP
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema

06 Nov 2026 SCHEDULE 13D/A
22 Oct 2026 Form 4: Column Group Iii GP, Lp, 10% owner and 6 others

Received 1,551,724 shares by exercise ($18M) · Acquired 775,862 Series E Common Warrants (In/At-money Exercise)

22 Oct 2026 SCHEDULE 13D/A
22 Oct 2026 Form 4: Kutzkey Tim, Director

Received 1,551,724 shares by exercise ($18M) · Acquired 775,862 Series E Common Warrants (In/At-money Exercise)

20 Oct 2026 8-K: Results of Operations and Financial Condition; Unregistered Sales of Equity Securities

Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143

07 Oct 2026 SCHEDULE 13G/A
02 Oct 2026 8-K: Other Events

On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The I...

01 Oct 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support